Evaluation of Effectiveness of vitamin D on immunity of atopic dermatitis patients
Phase 3
- Conditions
- Atopic dermatitis.Other atopic dermatitis
- Registration Number
- IRCT20150716023235N13
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients up to 50 years old who have clinical signs of atopic dermatitis
Low serum vitamin D levels
No oral drug for controlling atopic dermatitis recently
Exclusion Criteria
Patients with other atopic diseases
Having skin infections
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical symptoms of atopic dermatitis. Timepoint: At the beginning of the study (before the intervention) and 2 months after the start of the consumption. Method of measurement: SCORAD questionnaire.;Frequency of T reg cells in the blood. Timepoint: At the beginning of the study (before the intervention) and 2 months after the start of the consumption. Method of measurement: Flowcytometry.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does vitamin D modulate to increase Treg cell frequency in atopic dermatitis?
How does vitamin D supplementation compare to topical corticosteroids in regulating Treg cell activity for AD patients?
Which biomarkers correlate with Treg cell response to vitamin D in IRCT20150716023235N13 phase III atopic dermatitis trial?
What are the safety concerns and management strategies for high-dose vitamin D in phase III AD immunotherapy trials?
What combination therapies synergize with vitamin D to enhance Treg cell function in atopic dermatitis beyond monotherapy?